Biotest (TG:BIO)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Biotest Charts. Click Here for more Biotest Charts.](/p.php?pid=staticchart&s=TG%5EBIO&p=8&t=15)
Bio-Rad Laboratories, Inc. Announces Completion of Exchange Offer
of Its 6.125% Senior Subordinated Notes due 2014 for Registered Notes
HERCULES, Calif., June 1 /PRNewswire-FirstCall/ -- Bio-Rad Laboratories, Inc.
(Amex: BIO; BIOb), a multinational manufacturer and distributor of life science
research products and clinical diagnostics, announced today that it has
completed its offer to exchange (the "Exchange Offer") up to $200 million
aggregate principal amount of its 6.125% Senior Subordinated Notes due 2014
which have been registered under the Securities Act of 1933, as amended for any
and all of its outstanding 6.125% Senior Subordinated Notes due 2014 which were
issued in a private placement (the "Private Notes"). All of the $200 million
aggregate principal amount of the Private Notes were tendered and received
prior to expiration of the Exchange Offer at 5:00 p.m., New York City time, on
May 31, 2005.
This announcement is not an offer to exchange, or a solicitation of an offer to
exchange, with respect to the Private Notes. The Exchange Offer was made solely
by the prospectus dated May 2, 2005.
Bio-Rad Laboratories, Inc. (http://www.bio-rad.com/) is a multinational
manufacturer and distributor of life science research products and clinical
diagnostics. It is based in Hercules, California, and serves more than 70,000
research and industry customers worldwide through a network of more than 30
wholly owned subsidiary offices.
DATASOURCE: Bio-Rad Laboratories, Inc.
CONTACT: Christine Tsingos, Vice President and Chief Financial Officer,
or Ron Hutton, Treasurer, +1-510-724-7000, or ,
both of Bio-Rad Laboratories, Inc.
Web site: http://www.bio-rad.com/